Assessing the hemostasis with thromboelastometry in direct oral anticoagulants-treated patients with atrial fibrillation

•This study tested the ability of ROTEM® to identify changes in hemostasis in a real-world sample of DOACs-treated (dabigatran, rivaroxaban, and apixaban-treated) patients with atrial fibrillation.•Comparing DOACs-treated patients to healthy controls, significant differences were found in trough and peak CT-INTEM®, CT-EXTEM®, CT-FIBTEM®, and MCF-FIBTEM® for dabigatran, rivaroxaban, and apixaban.•Furthermore, for rivaroxaban, significant differences in CT-INTEM®, CT-EXTEM®, CT-FIBTEM® were present when trough and peak samples were compared.